

Galmed Pharmaceuticals

Galmed Pharmaceuticals to Provide Corporate Overview at the Stifel 2017 Healthcare Conference

TEL AVIV, Israel, Nov. 07, 2017 /PRNewswire/ --

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, today announced that its senior management will provide an overview of the scientific rationale and ongoing clinical development program of Aramchol™, a novel, once-daily, oral therapy for the treatment of NASH at the Stifel 2017 Healthcare Conference, being held at the Lotte New York Palace Hotel in New York City.

Galmed Pharmaceuticals Presentation Details:

Date: Wednesday, November 15

Time: 10:15 am Eastern Time

Location: Garrison room, 5th Floor

About Aramchol™ and Non-alcoholic Steatohepatitis (NASH)

Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol™'s ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating down regulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol™ on fibrosis is mediated by down regulation of steatosis and directly on human collagen producing cells. Aramchol™ has been granted Fast Track designation status by the FDA for the treatment of NASH.

NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.

About Galmed Pharmaceuticals Ltd.

Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol™, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations, as well as other liver associated disorders. Galmed is currently conducting the ARREST Study, a multicenter,

randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol™ in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Galmed also sponsors the ARRIVE Study, a proof-of-concept Phase IIa clinical trial designed to evaluate the safety and efficacy of Aramchol™ in up to 50 patients with HIV-associated NAFLD and lipodystrophy. The ARRIVE Study is an investigator-initiated trial, conducted at the University of California, San Diego by Professor Rohit Loomba. More information about the ARREST Study and the ARRIVE Study may be found on ClinicalTrials.gov identifiers: NCT02279524 and NCT02684591, respectively.

SOURCE Galmed Pharmaceuticals Ltd.

For further information: Bob Yedid, LifeSci Advisors, LLC, 646-597-6979, Bob@LifeSciAdvisors.com Guy Nehemya, VP Operations, Galmed Pharmaceuticals Ltd., guy@galmedpharma.com

Additional assets available online: [Photos \(1\)](#)

<https://galmedpharma.investorroom.com/2017-11-07-Galmed-Pharmaceuticals-to-Provide-Corporate-Overview-at-the-Stifel-2017-Healthcare-Conference>